Evidence map›Paper›PMID 28344878›Full record

ArticleOncoimmunology

Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.

Eva M Putz, Camille Guillerey, Kevin Kos, Kimberley Stannard, Kim Miles, Rebecca B Delconte, Kazuyoshi Takeda, Sandra E Nicholson, Nicholas D Huntington, Mark J Smyth

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Eva M PutzImmunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute , Herston, Queensland, Australia.
Camille GuillereyImmunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; School of Medicine, The University of Queensland, Herston, Queensland, Australia.
Kevin KosImmunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute , Herston, Queensland, Australia.
Kimberley StannardImmunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute , Herston, Queensland, Australia.
Kim MilesImmunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute , Herston, Queensland, Australia.
Rebecca B DelconteThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Victoria, Australia.
Kazuyoshi TakedaDepartment of Immunology, Juntendo University School of Medicine , Bunkyo-ku, Tokyo, Japan.
Sandra E NicholsonThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Victoria, Australia.
Nicholas D HuntingtonThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Victoria, Australia.
Mark J SmythImmunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; School of Medicine, The University of Queensland, Herston, Queensland, Australia.
QIMR Berghofer Medical Research Institute · AUThe University of Melbourne · AUThe University of Queensland · AUJuntendo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis.

Indexed as

Cancercytokine signalingimmunotherapymetastasisNK cells

Identifiers

PMID28344878
PMCPMC5353935
OpenAlexW2586111448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.